Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - terbutaline sulfate, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - indications ast at 24 june 2004: for relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm. bricanyl injection: bricanyl injection solution is recommended for acute use only.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bupivacaine hydrochloride monohydrate, quantity: 52.7 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - bupivacaine injection is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery - field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in post operative pain or labour pain. - field block (minor nerve block amd infiltration). the choice of 2 strengths, 0.25% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - potassium chloride, quantity: 750 mg - injection, concentrated - excipient ingredients: water for injections; potassium hydroxide; hydrochloric acid - indications as at august 2000: for the prevention and treatment of potassium deficiency (hypokalaemia). as an electrolyte supply. treatment of digitalis intoxication. these solutions are for use in patients who unable to take potassium orally. these solutions are for the preparation of dilute potassium chloride injections or for addition to intravenous fluids.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - tetracosactide 1 mg/ml equivalent to tetracosactide hexaacetate 1.12 mg/ml - injection (depot) - 1 mg/ml - active: tetracosactide 1 mg/ml equivalent to tetracosactide hexaacetate 1.12 mg/ml excipient: benzyl alcohol dibasic sodium phosphate dodecahydrate hydrochloric acid sodium chloride sodium hydroxide water for injection zinc chloride - diagnostic use for the investigation of adrenocortical insufficiency: a 5-hour test canbe peerformed using synacthen depot when the 30-minute test with synacthen i.m./i.v. gives inconclusive results, or if the aim is to determine the functional reserve of the adrenal cortex.

New Zealand - English - Medsafe (Medicines Safety Authority)

lumacina new zealand - water for injection 100% - solution for injection - 100 % - active: water for injection 100%

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - goserelin - injection - 10.8 mg/syringe - goserelin 10.8 mg/syringe

Singapore - English - HSA (Health Sciences Authority)

lundbeck singapore pte. ltd. - cis(z)-flupenthixol decanoate - injection - 20 mg/ml - cis(z)-flupenthixol decanoate 20 mg/ml

Malta - English - Medicines Authority

demo s.a. pharmaceutical industry 21st km national road athens - lamia 14568 krioneri, greece - water for, injections - solution for infusion or injection - water for injections 100 % (w/v) - all other non-therapeutic products

Malta - English - Medicines Authority

demo s.a. pharmaceutical industry 21st km national road athens - lamia 14568 krioneri, greece - water for, injections - solution for infusion or injection - water for injections 14.5 % (w/v) - all other non-therapeutic products

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.